Suppr超能文献

对促甲状腺激素释放激素的反应:促甲状腺激素抑制治疗充分性的客观标准。

Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.

作者信息

Hoffman D P, Surks M I, Oppenheimer J H, Weitzman E D

出版信息

J Clin Endocrinol Metab. 1977 May;44(5):892-901. doi: 10.1210/jcem-44-5-892.

Abstract

Most serum thyrotropin (TSH) assays do not adequately discriminate between normal values and absent TSH. We therefore evaluated the TSH response to thyrotropin releasing hormone (TRH) as a criterion for the adequacy of TSH suppression therapy. Twenty-six outpatients with various thyroid disorders (cancer, 10; nodules, 9; miscellaneous, 4; hypothyroidism after 131I therapy for Graves' disease, 3) were studied. Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, we first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period. In contrast, serum TSH was undetectable (less than 0.6 micronU/ml) throughout the 24-h period in 5 patients on TSH suppression therapy who were TRH-unresponsive and one who had a minimal response to TRH. Thus, TRH-unresponsive patients did not secrete measurable amounts of TSH throughout the 24-h period. To suppress TSH secretion, all patients were treated with L-thyroxine (T4) at doses which resulted in undetectable TSH values in random plasma samples. TRH tests were carried out only when random TSH concentrations were less than 0.6 micronU/ml. Seven of the twenty-six patients (27%) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion. In these seven, the T4 dose was adjusted until they were TRH-unresponsive. The mean change in T4 dose of these 7 patients was 20+/-10 (SD) microng/day and this resulted in a mean increase of 1.5+/-1.1 microng/dl for T4 and 20+/-20 ng/dl for T3. For all patients, the mean T4 dose required for TSH suppression was 172+/-53 microng/day or 2.6+/-0.8 microng per day per kg body weight. Twenty-three of 26 patients required between 100-200 microng/day and the remaining 3, 250-300 microng/day. The T4 dose required to suppress TSH resulted in normal serum concentrations of T4. 9.1+/-2.0 MICRONG/DL, AND T3, 136.7+/-33.6 NG/DL. These T4 doses did not produce a rapid heart rate, either awake or asleep, arrhythmias, or electrocardiographic abnormalties as assessed by 24-h Holter monitor tracings in 11 patients. Our results thus show that the T4 dose which results in an unresponsive TRH test ensures that serum TSH will remain undetectable (less than 0.6 micronU/ml) throughout the 24-h period. An unresponsive TRH test, therefore, appears to be a very useful and reliable index of TSH suppression.

摘要

大多数血清促甲状腺激素(TSH)检测方法无法充分区分正常数值和TSH缺失情况。因此,我们评估了TSH对促甲状腺激素释放激素(TRH)的反应,以此作为TSH抑制治疗是否充分的标准。我们研究了26例患有各种甲状腺疾病的门诊患者(癌症10例;结节9例;其他4例;格雷夫斯病131I治疗后甲状腺功能减退3例)。通过对两名正常志愿者和一名对TRH有反应的未治疗患者采用频繁采样技术(每20分钟采样一次),我们首先证实了TSH分泌在整个24小时内呈间歇性发生的观察结果。相比之下,5例接受TSH抑制治疗且对TRH无反应的患者以及1例对TRH反应极小的患者在整个24小时内血清TSH均无法检测到(低于0.6微单位/毫升)。因此,对TRH无反应的患者在整个24小时内均未分泌可测量量的TSH。为抑制TSH分泌,所有患者均接受左甲状腺素(T4)治疗,剂量调整至随机血浆样本中TSH值无法检测到。仅当随机TSH浓度低于0.6微单位/毫升时才进行TRH检测。26例患者中有7例(27%),包括2例甲状腺癌患者,对TRH有反应,表明有分泌TSH的潜力。在这7例患者中,调整T4剂量直至他们对TRH无反应。这7例患者T4剂量的平均变化为20±10(标准差)微克/天,这导致T4平均增加1.5±1.1微克/分升,T3平均增加20±20纳克/分升。对于所有患者,抑制TSH所需的平均T4剂量为172±53微克/天或2.6±0.8微克/天/千克体重。26例患者中有23例需要100 - 200微克/天,其余3例需要250 - 300微克/天。抑制TSH所需的T4剂量使血清T4浓度正常,为9.1±2.0微克/分升,T3为136.7±33.6纳克/分升。通过对11例患者进行24小时动态心电图监测,这些T4剂量在清醒或睡眠时均未导致心率加快、心律失常或心电图异常。因此,我们的结果表明,导致TRH检测无反应的T4剂量可确保血清TSH在整个24小时内均无法检测到(低于0.6微单位/毫升)。因此,TRH检测无反应似乎是TSH抑制的一个非常有用且可靠的指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验